ArticleFrontiers in immunology2018
Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 41 citations in OpenAlex.
- A New Immunofluorescence Assay Allows the Sensitive Detection of Anti-Cytosolic 5'-Nucleotidase 1A Autoantibodies.European journal of immunology · 2026Article
- Muscular involvement in Sjögren's disease is associated with male gender, Ro52 autoantibodies, and a higher clinical activity.Frontiers in medicine · 2026Article
- Overlap Myositis in a Patient With Psoriasis Treated With Anti-TNF-Alpha Therapy: A Case Report and Review of Literature.Case reports in rheumatology · 2026Article
- From Autoimmune Sialadenitis to Central Pain: Hypothesizing Shared Pathogenesis for Fibromyalgia and Primary Sjogren's Disease and Identifying Essential Screening Strategies.International journal of molecular sciences · 2025Article
- [Not just frailty-Sjögren's syndrome and polymyositis with mitochondrial pathology].Zeitschrift fur Rheumatologie · 2025Article
- Coexistence of CN1A autoantibodies in GAD65 encephalitis exacerbates neurodegeneration : Novel autoantibodies in GAD65 encephalitis.Journal of neuroinflammation · 2025Article
- Expression and Site-Specific Biotinylation of Human Cytosolic 5'-Nucleotidase 1A inMethods and protocols · 2025Article
- Idiopathic inflammatory myopathy associated with Sjögren's disease: features of a distinct clinical entity.Frontiers in immunology · 2025Article
- Sporadic Inclusion Body Myositis at the Crossroads between Muscle Degeneration, Inflammation, and Aging.International journal of molecular sciences · 2024Review
- Emerging biologic frontiers for Sjogren's syndrome: Unveiling novel approaches with emphasis on extra glandular pathology.Frontiers in pharmacology · 2024Review
- Anti-Cytosolic 5'-Nucleotidase 1A in the Diagnosis of Patients with Suspected Idiopathic Inflammatory Myopathies: An Italian Real-Life, Single-Centre Retrospective Study.Biomedicines · 2023Article
- Inborn Errors of Purine Salvage and Catabolism.Metabolites · 2023Review
- Anti-Valosin-Containing Protein (VCP/p97) Autoantibodies in Inclusion Body Myositis and Other Inflammatory Myopathies.ACR open rheumatology · 2023Article
- Uncovering the significance of expanded CD8Frontiers in immunology · 2023Article
- Potential common molecular mechanisms between Sjögren syndrome and inclusion body myositis: a bioinformatic analysis andFrontiers in immunology · 2023Article
- On the role of anti-cN1A antibodies in sporadic inclusion body myositis and beyond: a challenging task full of surprises.Reumatologia · 2023Article
- Inclusion Body Myositis and Neoplasia: A Narrative Review.International journal of molecular sciences · 2022Review
- Inclusion body myositis and associated diseases: an argument for shared immune pathologies.Acta neuropathologica communications · 2022Review
- 47XXY and 47XXX in Scleroderma and Myositis.ACR open rheumatology · 2022Article
- Myositis-specific Antibodies: Overview and Clinical Utilization.Rheumatology and immunology research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Autoantibodies to cytosolic 5'-nucleotidase 1A (cN-1A; NT5C1A) have a high specificity when differentiating sporadic inclusion body myositis from polymyositis and dermatomyositis. In primary Sjögren's syndrome (pSS) and systemic lupus erythematosus (SLE) anti-cN-1A autoantibodies can be detected as well. However, various frequencies of anti-cN-1A reactivity have been reported in SLE and pSS, which may at least in part be explained by the different assays used. Here, we determined the occurrence of anti-cN-1A reactivity in a large number of patients with pSS and SLE using one standardized ELISA. Methods: Sera from pSS ( Results: Anti-cN-1A autoantibodies were found on average in 12% of pSS patients, with varying frequencies among the different cohorts (range: 7-19%). In SLE patients, the anti-cN-1A positivity on average was 10% (range: 6-21%). No relationship was found between anti-cN-1A reactivity and the presence or absence of anti-Ro52, anti-nucleosome, and anti-dsDNA reactivity in both pSS and SLE. No relationship between anti-cN-1A reactivity and duration of disease at the moment of serum sampling and the duration of serum storage was observed. The frequency of muscular symptoms or viral infections did not differ between anti-cN-1A-positive and -negative patients. In both disease groups anti-cN-1A-positive patients suffered more often from other autoimmune diseases than the anti-cN-1A-negative patients (15 versus 5% ( Conclusion: Our results confirm the relatively frequent occurrence of anti-cN-1A in pSS and SLE patients and the variation in anti-cN-1A reactivity between independent groups of these patients. The explanation for this variation remains elusive. The correlation between anti-cN-1A reactivity and polyautoimmunity should be evaluated in future studies. We conclude that anti-cN-1A should be classified as a myositis-associated-, not as a myositis-specific-autoantibody based on its frequent presence in SLE and pSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.